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OBJECTIVES: To evaluate the cost-effectiveness (CE) immunization with 13-Valent 
Pneumococcal Conjugate Vaccine (PCV13) compared with no vaccination and also 
comparing with PCV10, considering direct effects in the Brazilian private market. 
METHODS: A decision tree model was used to estimate the total number of disease 
and disease sequels caused by S. pneumoniae and the clinical outcomes were mortality 
and incidence rates. The vaccination coverage rate was 90% considering a four-dose 
schedule, the pneumococcal disease according to the Brazilian label and the target 
population was a hypothetical birth cohort in Brazil followed 5 years from the Brazil-
ian Private Market Health care System perspective. RESULTS: Considering only direct 
costs and beneﬁts, the program with PCV13 comparing with PCV10 will avoid 60.652 
cases of disease including pneumonia and invasive disease, and also 133.615 saved 
life years. At a current vaccination’s price (PCV13 cost of R$ 198,11 and PCV10 R$ 
150,90) the CE results will be R$ 3.976,00 for life years gained and R$ 8.760,00 for 
disease averted. Considering the same price for PCV13 and PCV10, PCV13 will 
achieve cost-saving results. The program with PCV13 comparing with no vaccination 
will avoid 204.507 cases of disease including AOM, pneumonia and invasive disease, 
and also 162.239 saved life years. The CE results will be R$ 13.974,00 for life years 
gained and R$ 11.086,00 for disease adverted. CONCLUSIONS: The analysis sug-
gests that the PCV13 within the Brazilian private market expected to be very cost-
effective relative to PCV10 and to no vaccination. Considering the same price, PCV13 
comparing to PCV10 may result in reduction of mortality with resultant cost savings 
(R$ 35 Million).
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OBJECTIVES: To estimate the cost-effectiveness of the Advisory Committee on Immu-
nization Practices (ACIP) recommended schedule of adult immunizations in the US. 
METHODS: A cost-effectiveness calculator was constructed for the ACIP recom-
mended adult immunization schedule and included the following vaccination strategies 
(ages in years): Inﬂuenza (annually, age 50+), Hepatitis A/B (Hep A/B, college students 
age 18), Human Papillomavirus (HPV, women age 18–26), Pneumococcal Polysac-
charide (PPV, age 50+), Tetanus-Diphtheria acellular Pertussis (Tdap, age 20), Vari-
cella (age 20+), and Zoster (age 60+). Per-person estimates of discounted costs (2008$) 
and quality adjusted life years (QALYs) were derived from existing cost-effectiveness 
studies of target vaccinations vs. no vaccination. Two approaches were taken—cross-
sectional and longitudinal. In the cross-sectional approach, members of a hypothetical 
US-age-weighted cohort were assumed to receive the vaccinations for which they were 
eligible in a single year, lifetime incremental costs and QALYs were summed over the 
cohort, and an aggregate ICER calculated. In the longitudinal approach, incremental 
costs and QALYs from existing studies were applied to a cohort of 18 year-olds at 
the appropriate age for each vaccine; costs and QALYs were discounted to the present, 
summed, and an aggregate incremental cost-effectiveness ratio (ICER) was calculated. 
RESULTS: Estimated ICERs were $7300/QALY and $8000/QALY for the cross-
sectional and longitudinal approaches, respectively. Both approaches are inﬂuenced 
by inclusion of inﬂuenza vaccinations; however excluding inﬂuenza still results in 
cost-effective ICERs (below $30,000/QALY (cross-sectional) and below $20,000/
QALY (longitudinal)). In contrast, removing HPV, Hep A/B, PPV, Tdap, Varicella, or 
Zoster individually from the immunization schedule does not markedly alter the ICER. 
Advancing the cohort starting age from 18 to 65 years decreases the ICER to $5000/
QALY for the longitudinal approach. CONCLUSIONS: Independent of the analytic 
approach, adult immunization according to the current ACIP schedule is cost 
effective.
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OBJECTIVES: To evaluate cost-effectiveness of linezolid (LIN) vs vancomycin (VAN) 
for the empiric treatment of VAP-MRSA in Colombia. METHODS: A decision tree 
(validated by three infectologists, two intensivists) was designed to assess cost-effec-
tiveness of the two medications. The model simulated costs and effectiveness in a 
temporal horizon of 12 weeks, a third-payer perspective was used. Effectiveness and 
outcome measures were deﬁned as life-years gained (LYs). Clinical efﬁcacy and node 
probabilities were obtained by systematic literature review of published clinical trials, 
which estimated direct costs associated with VAP-MRSA treatment (drugs, hospital-
ization, and costs associated with adverse events). Medical costs from 3 major Colom-
bian cities were used; drug costs were taken from a standard costing source. 
Incremental cost per successfully treated patient (ICERs), one and two-way sensitivity 
analyses for key variables were performed for testing model’s robustness. RESULTS: 
Patients treated with LIN experienced the highest outcomes (6.6 LYs) followed by 
VAN (4.2 LYs). Mean cost per patient was lower for LIN (US$3150) compared to 
VAN (US$3400). The C/E Rate was better for LIN (US$474/LYs) compared to VAN 
(US$806/LYs). CONCLUSIONS: Linezolid is cost saving treatment compared to 
vancomycin in empiric treating mechanic ventilation associated pneumonia by meth-
icillin-resistant Staphylococcus aureus in Colombia.
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OBJECTIVES: To evaluate the cost-effectiveness of Pneumococcal Vaccine Polyvalent 
(PPSV23) in adults older than 60 years old in Colombia. METHODS: A systematic-
review was made to estimate the frequency and costs of pneumococcal pneumonia and 
meningitis in Colombia and the clinical course of the diseases. A database of consulta-
tions and hospitalizations in Colombia (RIPS) was searched. DALY’s were calculated 
from these data. Efﬁcacy and effectiveness of the vaccine was extracted from previous 
research. The time horizon of this study was 5 years. An univariate sensitivity analysis 
was made. Costs were expressed in US$ of 2008. RESULTS: 42,475 cases of pneumo-
nia for all causes were estimated for Colombia, which 4,446 (range: 2,395–8,159) are 
pneumococcal pneumonias, with 1290 deaths (range 470–3,134). A number of 474 
cases (range: 329–532) of pneumococcal meningitis are estimated, with 44 deaths 
(range: 34–81). Averted DALY in the base year was 4,262 (4,127 US$ per averted 
DALY), and in the ﬁfth year was 21,187 (543 US$ per averted DALY). In univariate 
analysis, at a cost of US$10 the vaccine resulted in 817 US$ per averted DALY for the 
base case. CONCLUSIONS: In developed countries immunization with PPSV23 is 
recommended in adults older than 60 years and other groups. This study shows that in 
Colombia, a developing country, this vaccine is cost-effective, at a GDP per capita of 
US$8500 in 2008. Despite the results, estimations would be different if the effectiveness 
of the vaccine in this population were signiﬁcatively different than assumed.
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AN INITIAL COST-EFFECTIVENESS ANALYSIS OF THE NEW 13-VALENT 
PNEUMOCOCCAL CONJUGATE VACCINE (PCV-13) VERSUS PCV-7 IN 
THE PUBLIC SECTOR OF HONG KONG
Lee KK, Chow DP, Lee VW
The Chinese University of Hong Kong, Hong Kong, China
OBJECTIVES: Local cost-effectiveness studies using local health data have supported 
the long-term health and economic beneﬁts of the PCV-7 due to herd immunity and 
have led to its inclusion in the routine immunization programme for infants in Hong 
Kong since September 2009. PCV-13 is due to be introduced in 2010. The aim of the 
present study is therefore to compare its clinical and economic impacts to those of the 
existing PCV-7 on the whole population of Hong Kong. METHODS: A decision 
analytical model modiﬁed from the recent Prevenar-13 Economic Impact (PREVENT) 
Model (RTI Health Solution) was used for the analysis of the outcomes of vaccination. 
The entire population of Hong Kong of around 7 million was analyzed with infants 
≤ 2 yo receiving PCV-7 vs PCV-13. Population data, incidence rates, serotype cover-
age, disease sequelae, mortality rates, vaccine effectiveness, duration of protection, 
herd effects, utilities, cost of vaccination, direct and indirect costs were adopted from 
local published studies, previous economic assessments of PCV-7 and PCV-13 and 
local government ﬁgures to populate the model. Sensitivity analyses were performed 
to check the robustness of the results. The time horizon was one year and the study 
was performed from a societal perspective. RESULTS: Over a period of 1 year, based 
on an assumption of 85% coverage in infants, our analysis showed for a 4-dose 
regimen of PCV-13 as compared to a 4-dose PCV-7: a gain of 6 life-years and 5 
quality-adjusted-life-years (QALY); an avoidance of 108 related illnesses (including 
bacteraemia, all-cause pneumonia, meningitis and otitis media) and 1 death; cost/
life-year-gained was −US48,044, cost/QALY was −US53,383, and cost/illness avoided 
was −US 2,702. CONCLUSIONS: Based on this initial analysis, our study results 
suggest PCV-13 vaccination dominates PCV-7 in providing protection to the people 
of Hong Kong. Health authority should therefore consider replacing PCV-7 with 
PCV-13 in due course.
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OBJECTIVES: Diabetic foot infection is a frequent complication for diabetes patients 
that lead to high economical costs. The purpose of this study was to develop an eco-
